vTv Therapeutics Inc. Class A Common Stock
VTVTvTv Therapeutics Inc. Class A (VTVT) is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases and diabetes. The company leverages proprietary technologies to pioneer novel treatment options, with an emphasis on improving patient outcomes in chronic and traditionally underserved conditions.
Company News
vTv Therapeutics appointed a Scientific Advisory Board of distinguished clinicians and scientists to provide strategic guidance on cadisegliatin, a potential oral treatment for type 1 diabetes currently in Phase 3 clinical trials.
vTv Therapeutics received a USPTO patent for crystalline forms of cadisegliatin, a potential oral treatment for Type 1 diabetes, with patent protection extending through 2041.
vTv Therapeutics has appointed Michael Tung as its new Chief Financial Officer. The company has also reinitiated screening in its CATT1 Phase 3 trial for cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for the treatment of type 1 diabetes.
The type 1 diabetes (T1D) market is expected to grow at a strong CAGR of 13.3% from 2023 to 2033, reaching $9.91 billion. Key drivers include the increased use of rapid-acting insulins, insulin pumps, and immunomodulatory therapies, as well as the rising global prevalence of T1D. However, high prices, patent expiries, and the failure of disease-m...
Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D
